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Abstract
Objective: To assess the clinical and laboratory predictors of venous thromboembolism (VTE)
in patients with sickle cell anaemia (SCA) and its relationship to morbidity and mortality.
Methods: This retrospective case–control study analysed data from patients with SCA that
experienced VTE compared with matched control patients with SCA but no VTE (2:1 ratio).
Results: A total of 102 patients with SCA were enrolled (68 cases with VTE and 34 controls).
Amongst the 68 cases (median age, 29.5 years), 26 (38.2%) presented with isolated pulmonary
embolism (PE). A higher prevalence of splenectomy (73.5% versus 35.3%) was observed in the
cases compared with the controls. A significantly higher prevalence of central venous catheter
(CVC) insertion (42.6% versus 8.8%) was observed in the cases compared with the controls. High
white blood cell counts, serum lactic dehydrogenase (LDH), bilirubin and C-reactive protein
(CRP) and low haemoglobin (Hb) and HbF were significant risk factors for VTE. Forty-two
cases (61.8%) developed acute chest syndrome, 10 (14.7%) had a stroke and seven (10.3%) died.
Conclusions: VTE in patients with SCA has a high impact on morbidity and mortality. PE was the
leading presentation of VTE, with CVC insertion, high LDH, bilirubin, CRP and white blood cell
counts along with low Hb and HbF constituting other significant risk factors.
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Introduction
Sickle cell anaemia (SCA) is a common and
life-threatening haematological disorder
that affects millions of people worldwide.1,2
In Oman, SCA is a major public concern,
where 5.7% of the population carry the
sickle cell gene and 0.3% Omani people
have SCA.3,4 It is a monogenic recessively
inherited disorder with abnormal betaglobin alleles, where glutamic acid is
replaced by valine in the haemoglobin subunit beta (HBB) gene.5,6 Upon deoxygenation, this genetic mutation causes
erythrocytes to undergo intracellular polymerization in which flexible biconcave
shaped red cells change into an elongated
rigid form (sickled cells). As the process of
sickling and unsickling continues, the erythrocyte membrane loses the flexibility to
change and the cell remains permanently
sickled.7 Sickled red blood cells are rigid
with a non-deformable membrane and are
prematurely destroyed leading to a chronic
haemolytic anaemia.1,7 The intravascular
haemolysis of red blood cells results in elevated free plasma haemoglobin with depletion of nitric oxide in the microcirculation
contributing to the high prevalence of morbidity and mortality in adults with SCA.8
Sickled erythrocytes occlude blood vessels and disrupt blood flow, causing repeated ischaemia and inflammation. This vessel
occlusion is a complex process involving an
interaction between the sickle cell, vessel
endothelial cells, platelets and other blood
components.9,10 The adherence of the sickle
cell to the vessel endothelium results in activation of the endothelial cells and secretion

of inflammatory mediators and biomarkers
that increase platelet activation and induce
blood coagulation.10
Patients with SCA frequently develop
acute pulmonary complications, including
acute chest syndrome (ACS), asthma and
a higher risk for thromboembolism.11–13
Several mechanisms have been suggested
to explain this hypercoagulability including
platelet reactivity, with elevated plasma
concentrations of platelet-derived microparticles, hydroxyl radical formation, fibronectin and thrombospondin elevation,
deficient proteins S and C, and elevated
levels of factor VIII and tissue factor.14,15
Several studies in SCA patients have
recorded a high prevalence of venous
thromboembolism (VTE).16–18 These studies found that the incidence of VTE events
in SCA patients was higher than in the nonSCA population.16–18 Also, several laboratory parameters were abnormal in the
patients with VTE such as heterozygosity
for factor V Leiden, elevated platelet
counts as well as high factor VIII: C
levels.18 A previous study that investigated
the prevalence of pulmonary embolism (PE)
and deep vein thrombosis (DVT) in SCA
patients reported that 0.44% of patients
had a discharge diagnosis of PE and
DVT, as compared with 0.12% of nonSCA patients, indicating a significantly
high prevalence.18 A previous study
reported that the cumulative incidence of
VTE was 17.1% for severe sickle cell disease (SCD) patients (hospitalized 3 times
a year) versus 8.0% for the matched asthma
controls and was associated with increased
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mortality.19 The Cooperative Study of
Sickle Cell Disease on 1523 SCD patients
aged 15 years with 8862 years of followup reported an incidence rate for first VTE
of 5.2 events/1000 person-years (95% confidence interval [CI] 3.8, 6.9) with a cumulative incidence of 11.3% (95% CI 8.3, 15.3)
by age 40 years.20 Thus, it is apparent that
SCA is a risk factor for DVT and PE.
This current study aimed to assess the
clinical and pathological characteristics of
VTE amongst patients with SCA in order
to determine the predisposing factors and
determine its impact on morbidity and
mortality.

Patients and methods
Patient population
This retrospective case–control study
enrolled consecutive patients presenting
with thromboembolic complications including unprovoked PE, upper and lower
extremity DVT, portal vein thrombosis
(PVT), superior vena cava thrombosis,
right atrial thrombosis and cerebrovascular
accident (CVA) in the Department of
Haematology, Sultan Qaboos University
Hospital, Muscat, Oman between January
2007 and January 2018. The inclusion criterion for the case group was patients with
SCA that were admitted with venous
thrombosis or thromboembolic complications. Patients that had SCA without
thrombosis that attended the outpatient
clinic of the Department of Haematology,
Sultan Qaboos University Hospital for routine appointments and prescription medication or were admitted for pregnancy formed
the control group in a ratio of 2:1 due to the
consecutive enrolment during the study
period. None of the patients included in
the study were on a regular transfusion protocol for the prevention of SCA complications. All the patients in this study were
confirmed to have SCA by high
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performance liquid chromatography. All
patient data were collected from the hospital information system at the Sultan
Qaboos University Hospital.
The Medical Research Ethics Committee
of the Sultan Qaboos University Hospital
approved the study (no. MREC 1491).
Patient consent was not required due to
the retrospective design of the study. The
reporting of this study conforms to
STROBE guidelines.21

Data collection
The data collected from the hospital information system included age, sex and SCAassociated complications, such as frequency
of vaso-occlusive crisis (VOC), ACS, splenic sequestration and febrile episodes. The
VOC frequency was categorized as high
(>6 VOC/year), moderate (3–6 VOC/year)
and low frequency (1–2 VOC/year). ACS
was defined as patients presenting with
fever and/or respiratory symptoms, accompanied by new infiltrates on the chest radiograph. Steady state was defined as the
absence of fever or VOC in the previous
4 weeks in the patient. Amongst the
cases and controls, asplenia was defined as
splenic atrophy as confirmed by ultrasound/computed tomography (CT) scan
and/or past surgical splenectomy. All central venous catheter (CVC) lines used in
these patients included peripherally inserted
central lines, PORT-A-CATHVR , regular
central line in the neck and femoral lines.
The type of thrombosis, CVC insertion,
hydroxyurea (HU) use and pregnancy
details were recorded as clinical parameters.
Laboratory data were recorded at baseline
and during the thromboembolic episode in
the cases. Haematological parameters
included haemoglobin (Hb) level, white
blood cell (WBC) and platelet counts,
reticulocyte %, HbS% and HbF%.
Biochemical parameters included serum
total bilirubin, serum lactic dehydrogenase
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(LDH), serum vitamin B12, serum fibrinogen, D-dimer and C-reactive protein (CRP).
In addition, the radiological results of magnetic resonance imaging, CT angiography
and abdominal ultrasound were recorded.
The impact of VTE on morbidity and mortality in all patients was determined. VTEs
were managed using a standard international protocol based on the American College
of Chest Physicians guidelines.20

U-test was used to compare the continuous
data between the case and control groups;
and between baseline and the VTE episode
in the case group. Categorical data are
presented as frequency of patients.
Independent t-test was used to compare
the continuous data between the case and
control groups. v2-test was used to compare
the categorical data between the case and
control groups. A P-value <0.05 was considered statistically significant.

Statistical analyses
All statistical analyses were performed
using IBM SPSS Statistics for Windows,
Version 23.0 (IBM Corp., Armonk, NY,
USA). Normally distributed continuous
data are presented as mean  SD.
Continuous data that were not normally
distributed are presented as median with
interquartile range (IQR). Mann–Whitney

Results
This retrospective case–control study
enrolled 102 patients with SCA. Table 1
shows the demographic and clinical characteristics of the cases (n ¼ 68) and controls
(n ¼ 34). The median age of the cases was
29.5 years (IQR 24.3, 35.0; range, 12–80
years) compared with 33.0 years (IQR

Table 1. Demographic and clinical characteristics of patients with sickle cell anaemia with (case group,
n ¼ 68) and without (control group, n ¼ 34) venous thromboembolism (VTE).
Characteristic
Age, years
Sex, male:female
Age in males, years
Age in females, years
Haemoglobin genotype
HbSS homozygotes
Hb b-Thal/HbS
History of ACS
History of splenomegaly
History of splenectomy
VOC/year, 1–2
VOC/year, 3–6
VOC/year, >6
History of hydroxyurea therapy
History of previous pregnancy
History of pulmonary embolism
in pregnancy or puerperium

Case group
n ¼ 68

Control group
n ¼ 34

Statistical
analysesa

29.5 (24.3, 35.0)
24:44
27.5 (24.0, 30.0)
33.0 (25.0, 36.0)

33.0 (24.0, 41.3)
16:18
39.5 (32.0, 45.3)
26.5 (24.0, 31.3)

NS
NS
NS
NS

64
4
56
7
50
25
18
28
36
12
16

(94.1)
(5.9)
(82.4)
(10.3)
(73.5)
(36.8)
(26.5)
(41.2)
(52.9)
(27.3)
(36.4)

30
2
22
6
12
17
12
5
21
3
0

(88.2)
(5.9)
(64.7)
(17.6)
(35.3)
(50.0)
(35.3)
(14.7)
(61.8)
(16.7)
(0.0)

NS
NS
NS
NS
NS
NS
NS
P ¼ 0.04
NS
NS
P < 0.05

Data presented as median (interquartile range) or n of patients (%).
a 2
v -test was used to compare the categorical data between the case and control groups; NS, no significant between-group
difference (P  0.05).
ACS, acute chest syndrome; VOC, vaso-occlusive crisis.
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24.0, 41.3; range, 12–55 years) for the control group. There were no significant differences in age and sex distribution between
the two groups. Asplenia (including autosplenectomy) was observed in 50 (73.5%)
cases compared with 12 (35.3%) controls,
but the difference did not reach significance
(Table 1). There was a significantly higher
proportion of patients in the case group
with high VOC frequency (>6/year) compared with the control group (P ¼ 0.04).
There were no significant differences
between the two groups in terms of Hb
genotype, history of ACS, history of
splenomegaly, history of HU therapy or
the rate of pregnancy. A history of PE
during pregnancy or puerperium (up to 6
weeks after delivery) was observed significantly more often in the case group than the
control group (P < 0.05).
Amongst the haematological parameters
(Table 2), there were significant differences
between the two groups at baseline in Hb,
WBC count, reticulocytes, HbS% and HbF

% (P < 0.05 for all comparisons). CRP,
LDH and total bilirubin were all significantly higher in the cases compared with
the controls (P < 0.05 for all comparisons).
There were no significant differences
between the two groups in terms of kidney
function, liver function, tobacco use or ferritin levels (data not shown).
The pattern of thromboembolism in the
study population is shown in Table 3.
Isolated PE and upper and lower limb
DVT were the predominant presentations
in the case group. Among the risk factors
for thromboembolic complications, the rate
of CVC insertion was significantly higher in
the case group compared with the control
group (P < 0.05). There were no significant
differences in the rate of ACS or stroke
between the two groups. The mortality
rate was significantly higher in the case
group compared with the control group
(P < 0.05). Mortality in the case group
was 10.3% (n ¼ 7), of which five died after

Table 2. Laboratory parameters in patients with sickle cell anaemia with (case group, n ¼ 68) and without
(control group, n ¼ 34) venous thromboembolism (VTE).
Case group n ¼ 68

Control group
n ¼ 34

Statistical
analysesa

Parameter

At VTE
episode

At baseline versus
at VTE episode

At baseline

Cases versus
controls

Haemoglobin, g/dl
White blood cell count, 109/l
Reticulocytes, %
Platelet count, 109/l
Haemoglobin S,%
Haemoglobin F, %
Fibrinogen, g/l
Vitamin B12, pmol/l
Serum lactic dehydrogenase, u/l
C-reactive protein, mg/l
Serum total bilirubin, mg/dl
Elevated D-Dimers

8.5
12.7
5.3
392
78.2
5
4
222.5
483
45
39.5
37 (54.4)

9.7
10.1
5.4
400

P < 0.05
P < 0.05
NS
NS

292

P < 0.05

25.0

P ¼ 0.03

9.9
8.9
4.2
343
84.5
8.5
3.2
253.5
334
7
28.5
0 (0.0)

P < 0.05
P < 0.05
P < 0.05
NS
P < 0.05
P < 0.05
NS
NS
P < 0.05
P < 0.05
P < 0.05
–

Data presented as median or n of patients (%).
a
Mann–Whitney U-test was used to compare the continuous data between the case and control groups; and between
baseline and the VTE episode in the case group; NS, no significant between-group difference (P  0.05).
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Table 3. Comparison of events and outcomes in patients with sickle cell anaemia with (case group, n ¼ 68)
and without (control group, n ¼ 34) venous thromboembolism (VTE).
Outcomes

Case group
n ¼ 68

Isolated PE
DVTb
Upper extremity DVT
Lower extremity DVT
Other VTEs
Ischaemic cerebral event
Right atrial and SVC thrombosis
Abdominal vessel thrombosis
Combined PE þ VTE/DVTs
CVC insertion
PE with CVC
Upper limb DVT with CVC
Lower limb DVT with CVC
ACS
Stroke
Death

26
25
13
12
17
10
2
5
6
29
7
18
4
42
10
7

(38.2)
(36.8)
(52.0)
(48.0)
(25.0)
(58.8)
(11.8)
(29.4)
(8.8)
(42.6)
(24.1)
(62.1)
(13.8)
(61.8)
(14.7)
(10.3)

Control group
n ¼ 34
0 (0.0)
0
0
0
0
0
0
0
3
0
0
0
22
2
0

(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(8.8)
(0.0)
(0.0)
(0.0)
(64.7)
(5.9)
(0.0)

Statistical
analysesa
P < 0.0005
P ¼ 0.002
P ¼ 0.002
P ¼ 0.005
P ¼ 0.005
NS
P ¼ 0.04
P ¼ 0.03
P < 0.05
P ¼ 0.02
P ¼ 0.0002
NS
NS
NS
P < 0.05

Data presented as n of patients (%).
a 2
v -test was used to compare the categorical data between the case and control groups; NS, no significant between-group
difference (P  0.05).
b
Upper extremity DVT: axillary, subclavian, internal jugular; Lower extremity DVT: all lower limb up to the iliac veins.
PE, pulmonary embolism; DVT, deep vein thrombosis; SVC, superior vena cava; CVC, central venous catheter; ACS, acute
chest syndrome.

a PE episode and two died after having an
ischaemic stroke.
There were moderate correlations
between VTE and PE and CVC insertion,
with correlation coefficients of r ¼ 0.35 and
r ¼ 0.3, respectively.

Discussion
Several studies have shown that VTE is one
of the common complications of SCA with
a cumulative incidence that increases with
the age, with the mean age ranging from
24 to 37 years.18,19,22 Researchers have
also compared SCA with inherited thrombophilia with a thrombosis prevalence
around 25%, which is similar to those
seen in a family with strong thrombophilic
defects.23 In this current retrospective
study, the median age of SCA patients

that developed VTE was 29.5 years (range,
12–80 years), which was not significantly
different from the median age of the control
group (33.0 years) and similar to previous
research.19 However, it was lower than the
median age of 68 years for thrombosis seen
in the general population.24 In addition, the
current study found that sex was not a risk
factor for VTE in patients with SCA, but
the prevalence data indicated a preponderance for females, probably driven by pregnancy, although it did not reach statistical
significance. These data were similar to
another study from the US in which females
were more at risk for VTE than males,
again, not in keeping with the observations
in the general population.19
The spectrum of thrombosis in the current study cohort revealed that DVT/VTEs
(n ¼ 42) were seen in more than half of the
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cases as compared with isolated PEs
(n ¼ 26). This has been reported in the previous studies.17,19 A previous study
observed that the prevalence of DVT in
SCA and non-SCA patients was similar,
whereas, the prevalence of PE in SCA
patients was twice that of non-SCA
patients.18 It has been suggested that
thrombosis-in-situ could be responsible for
this striking difference and that PE may be
an aetiological factor in SCA patients that
develop respiratory symptom.25 Pulmonary
hypertension with tricuspid regurgitation
jet velocity 2.5 m/s is linked to VTE.26
Although, SCD is a hypercoagulable state,
the contribution of VTE to an elevated tricuspid regurgitation velocity is unknown.26
This raises the possible pathogenic link
between large-vessel venous thrombosis
and the small-vessel thrombi observed in
patients with sickle cell with pulmonary
hypertension.27 Although this current
study found a high rate of PE and VTE,
arterial thrombosis was rarely seen (one
case each, for cerebral arterial and portal
arterial thrombosis, but excluded from current data analysis).
One of the aims of this current study was
to identify the predisposing factors that
increase the risk of developing VTE in
patients with SCA. There are a number of
potential predisposing factors to thrombosis in SCA, including frequent hospitalizations,
raised
inflammation
and
hypercoagulable state associated with this
disease, however, those factors are not
well studied. Although the increased frequency of VOC is not a direct risk factor,
it could be considered as a surrogate factor,
since it leads to frequent and prolonged
hospitalization of SCA patients, which is a
risk factor for thromboembolism. This current study found that patients with more
frequent VOCs had a significantly higher
prevalence of VTE. This may again reflect
disease severity and has been seen in other
research.19 This current study found that a
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high percentage of the VTE patients had a
history of ACS (82.4%), implying that it
did predispose to the occurrence of VTE,
and such patients suffered from ACS as a
complication of PE. Furthermore, previous
research has demonstrated that PE is considered to significantly predispose for ACS,
with PE episodes developing during ACS,25
which is again similar to these current
observations. However, it is difficult to conclude (from the current data), whether PE is
a cause or a consequence of ACS.28 It is
believed that patients with SCA are more
prone to infection as a result of immune
impairment
because
of
asplenia.29
Infection, by promoting an increase in
inflammatory cytokines, can provoke
thrombosis,
especially
in
asplenic
patients.30 Furthermore, asplenia in haemolytic diseases including SCA was reported
to be associated with an increased risk of
thrombosis, as seen in this current study.16
Central venous catheter insertion has a
significant correlation with VTE episodes.15
CVC is generally required for many
patients with SCA and it has been shown
to be an independent risk factor for
VTE.15,31 Furthermore, prolonged use of
catheter implantation increases the risk of
thrombosis,17,31 as seen in the current study
cohort. Among the 68 patients with VTE in
the case group, 29 patients had CVC at the
time of VTE, including 18 with upper limb
DVT, seven with PE and four had lower
limb DVT.
Pregnancy is significantly correlated with
VTE as the rate of VTE during pregnancy
and puerperium was 1.5–2.5-times greater
than in non-pregnant SCA women.32,33 It
is reported that pregnancy-related VTE in
females with SCA is 1.5–5-times greater
than pregnancy-related VTE in the general
population.32 The current study demonstrated that 27.3% of cases compared with
16.7% of controls had a history of pregnancy. Interestingly, PE was reported in 16
(36.4%) of females in the case group,
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whereas none of the three pregnant females
in the control group developed PE
(P < 0.05). There are several possible
explanations for this, such as impaired
venous return from lower limbs, high level
of steroid hormones and changes in the haemostatic system, in addition to SCA, which
together contribute to elevate the risk of
thrombosis
during
the
pregnancy
period.32,33 This has led to the recommendation of prophylactic anticoagulation in
all pregnant patients with SCA.34
The use of HU therapy over the last 30
years has been shown to increase HbF in
SCA patients leading to improved clinical
efficacy.35 It is associated with a reduction
in the levels of biomarkers of hypercoagulability in SCA patients and is likely to
reduce the prevalence of VTE.36 In this
current study, the median HbF levels
were significantly higher in the control
group compared with the case group.
Furthermore, a higher percentage of control patients (61.8%) were treated with
HU compared with 52.9% in the case
group, which might explain the higher
median HbF in the controls. Although
there are contradicting results on the
impact of HU on VTE prevention, these
current results were in inconclusive with
respect to a positive role of HU in VTE
prevention, knowing that that HbF inhibits
intracellular HbS polymerization.37,38
In the current study population, there
were elevations in the median WBC count,
LDH level, bilirubin and CRP in the case
group from baseline to VTE episode; and
the baseline levels were significantly different compared with the control group.
Higher WBC count and elevated LDH
level are reported to be risk factors for
VTE in SCA.39 Biomarkers are helpful in
identifying different pathophysiological
mechanisms in SCA, including hypercoagulability, haemolysis, nitric oxide depletion, inflammation, oxidative stress,
vasculopathy, reperfusion injury and tissue
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necrosis with infarction.7–10,19,25Over half
of the patients in the case group in the current study had elevated D-dimer (54.4%) at
the VTE episode and the CRP levels were
significantly higher at the VTE episode
compared with the controls at baseline,
which were presumably due to an acute
phase reaction, often seen in patients with
thromboembolism and in sickle cell crisis.33
Among the clinical complications of
VTE in this current group of patients, a
large majority of the patients in the case
group developed ACS (61.8%), which was
consequential of the development of PE;
and 10 patients (14.7%) developed stroke
as a manifestation of venous and arterial
thrombosis within cerebral vessels. In 306
autopsies of SCA patients, a previous
study reported that 9.8% died due to
stroke and 4.9% died due to pulmonary
However,
another
emboli/thrombi.40
autopsy study from Nigeria reported that
the mortality rate from fatal thromboembolic complications was 37%.41 Thus,
although infections and multiorgan failure
are major causes of death in SCA, SCA with
VTE is still associated with a significant
mortality.40,41 These data support the regular use of prophylactic low molecular weight
heparin for the purpose of VTE prevention
and improved VOC management.42,43
In conclusion, acknowledging the limitation of the retrospective nature of this current study, VTE was one of the common
complications of SCA and it occurred at a
younger age than the general population.
PE showed a higher prevalence in patients
with SCA. Several risk factors contributed
to the development of VTE in patients with
SCA such as CVC insertion and pregnancy.
In addition, coagulation activity in patients
with SCA was enhanced with abnormal
activation of the fibrinolytic system and
increased levels of WBCs, LDH, bilirubin
and CRP. This current study demonstrated
that thromboembolic complications in
patients with SCA had a high impact on
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morbidity and mortality and calls for the use
of prophylactic anticoagulation in all
patients with SCA during their hospital stay.
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